FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a liquid oral solution for treating angiotensin II mediated disorders and conditions, and to a method for preparing it. The liquid oral solution contains valsartan in the concentration of 5 mg/ml or less, a wetting agent, a preserving agent, a flavouring agent, a buffer system and water with pH of the solution making 4.5-5.9. The wetting agent is poloxamer 188 described by the structure HO(CH2CH2O)a(CH(CH3)CH2OH)b(CH2CH2O)cH, wherein a is equal to 75, b is equal to 30, and c is equal to 75, with average molecular weight 8350. The buffer system contains alkali citrates and citric acid, alkali acetates and acetic acid, alkali succinates and succinic acid, or any mixtures thereof. The method for preparing the above solution involves mixing the ingredients added then with valsartan when heated.
EFFECT: group of inventions provides preparing the liquid solution of valsartan with an extended storage period.
8 cl, 12 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION OF VALSARTAN | 2008 |
|
RU2487710C2 |
THE COMPOSITION OF FENFLURAMINE, COMPATIBLE WITH A KETOGENIC DIET | 2018 |
|
RU2778848C2 |
PHARMACEUTICAL COMPOSITION CONTAINING 5-METHYL-2-(2′-CHLORO-6′- FLUOROANILINE)PHENYLACETIC ACID | 2004 |
|
RU2363462C2 |
PHARMACEUTICAL SUSPENSIONS, WHICH DO NOT CONTAIN COLOURING AGENTS, AND METHODS OF OBTAINING THEM | 2005 |
|
RU2395275C2 |
COMBINATION OF ORGANIC COMPOUNDS | 2003 |
|
RU2324482C2 |
ORAL SUSPENSION CONTAINING HIGH DOSE OF MOFETIL MYCOPHENOLATE | 1994 |
|
RU2150942C1 |
LIQUID PHARMACEUTICAL COMPOSITION CONTAINING NITIZINONE | 2012 |
|
RU2605301C2 |
ADMINISTRATION OF RENIN INHIBITORS FOR PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE | 2005 |
|
RU2407523C2 |
PAZOPANIB COMPOSITION | 2012 |
|
RU2616500C2 |
PREGABALIN COMPOSITION | 2004 |
|
RU2352333C2 |
Authors
Dates
2013-07-27—Published
2008-11-10—Filed